PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer

NCT04539977 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Small-cell Lung Cancer

Interventions

DRUG: TQB2450
DRUG: TQB2450

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China